129 related articles for article (PubMed ID: 38317480)
1. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment.
Symington E; Rangarajan S; Lester W; Madan B; Pierce GF; Raheja P; Robinson TM; Osmond D; Russell CB; Vettermann C; Agarwal SK; Li M; Wong WY; Laffan M
Haemophilia; 2024 Mar; 30(2):320-330. PubMed ID: 38317480
[TBL] [Abstract][Full Text] [Related]
2. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
Pasi KJ; Laffan M; Rangarajan S; Robinson TM; Mitchell N; Lester W; Symington E; Madan B; Yang X; Kim B; Pierce GF; Wong WY
Haemophilia; 2021 Nov; 27(6):947-956. PubMed ID: 34378280
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
Oldenburg J; Chambost H; Liu H; Hawes C; You X; Yang X; Newman V; Robinson TM; Hatswell AJ; Hinds D; Santos S; Ozelo M
Adv Ther; 2024 Jun; 41(6):2267-2281. PubMed ID: 38616241
[TBL] [Abstract][Full Text] [Related]
5. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
[TBL] [Abstract][Full Text] [Related]
6. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
[TBL] [Abstract][Full Text] [Related]
7. Valoctocogene Roxaparvovec: First Approval.
Blair HA
Drugs; 2022 Sep; 82(14):1505-1510. PubMed ID: 36214970
[TBL] [Abstract][Full Text] [Related]
8. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
[TBL] [Abstract][Full Text] [Related]
9. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
Madan B; Ozelo MC; Raheja P; Symington E; Quon DV; Leavitt AD; Pipe SW; Lowe G; Kenet G; Reding MT; Mason J; Wang M; von Drygalski A; Klamroth R; Shapiro S; Chambost H; Dunn AL; Oldenburg J; Chou SC; Peyvandi F; Millar CM; Osmond D; Yu H; Dashiell-Aje E; Robinson TM; Mahlangu J
J Thromb Haemost; 2024 Apr; ():. PubMed ID: 38614387
[TBL] [Abstract][Full Text] [Related]
10. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A.
Long BR; Robinson TM; Day JRS; Yu H; Lau K; Imtiaz U; Patton KS; de Hart G; Henshaw J; Agarwal S; Vettermann C; Zoog SJ; Gupta S
Mol Ther; 2024 May; ():. PubMed ID: 38796703
[TBL] [Abstract][Full Text] [Related]
11. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
[TBL] [Abstract][Full Text] [Related]
12. Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec.
Zhang L; Handyside B; Murphy R; Sihn CR; Xie L; Vitelli C; Harmon D; Sisó S; Liu S; Bullens S; Bunting S; Fong S
Mol Ther Methods Clin Dev; 2020 Jun; 17():13-20. PubMed ID: 31890737
[TBL] [Abstract][Full Text] [Related]
13. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A.
Agarwal S; Hermans C; Miesbach W; Peyvandi F; Sidonio R; Osmond D; Newman V; Henshaw J; Pipe S
Haemophilia; 2024 Apr; ():. PubMed ID: 38684460
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.
O'Mahony B; Dunn AL; Leavitt AD; Peyvandi F; Ozelo MC; Mahlangu J; Peerlinck K; Wang JD; Lowe GC; Tan CW; Giermasz A; Tran H; Khoo TL; Cockrell E; Pepperell D; Chambost H; López Fernández MF; Kazmi R; Majerus E; Skinner MW; Klamroth R; Quinn J; Yu H; Wong WY; Robinson TM; Pipe SW
J Thromb Haemost; 2023 Dec; 21(12):3450-3462. PubMed ID: 37678546
[TBL] [Abstract][Full Text] [Related]
15. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A.
Cook K; Forbes SP; Adamski K; Ma JJ; Chawla A; Garrison LP
J Med Econ; 2020 May; 23(5):501-512. PubMed ID: 31971453
[No Abstract] [Full Text] [Related]
16. Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B.
Dougherty JA; Dougherty KM
Ann Pharmacother; 2023 Nov; ():10600280231202247. PubMed ID: 37978816
[TBL] [Abstract][Full Text] [Related]
17. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
[TBL] [Abstract][Full Text] [Related]
18. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
Leavitt AD; Konkle BA; Stine KC; Visweshwar N; Harrington TJ; Giermasz A; Arkin S; Fang A; Plonski F; Yver A; Ganne F; Agathon D; Resa MLA; Tseng LJ; Di Russo G; Cockroft BM; Cao L; Rupon J
Blood; 2024 Feb; 143(9):796-806. PubMed ID: 37871576
[TBL] [Abstract][Full Text] [Related]
19. Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer.
Sandza K; Clark A; Koziol E; Akeefe H; Yang F; Holcomb J; Patton K; Hammon K; Mitchell N; Wong WY; Zoog SJ; Kim B; Henshaw J; Vettermann C
Gene Ther; 2022 Feb; 29(1-2):94-105. PubMed ID: 34421119
[TBL] [Abstract][Full Text] [Related]
20. The Arrival of Gene Therapy for Patients with Hemophilia A.
Castaman G; Di Minno G; De Cristofaro R; Peyvandi F
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
